Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat

详细信息    查看全文

• 作者：Kenneth Kin-Wah To^a ; ^{kennethto@cuhk.edu.hk} ; Wing-Sum Tong^a ; Li-wu Fu^b
• 关键词：ABC ; ATP-binding cassette ; CFDA ; carboxy-2&rsquo ; 7&rsquo ; -dichlorofluorescein diacetate ; MDR ; multidrug resistance ; NC2 ; negative cofactor 2 ; NSCLC ; non-small cell lung cancer ; Pt ; platinum ; SRB ; sulforhodamine B
• 刊名：Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：103
• 期：Complete
• 页码：58-65
• 全文大小：1401 K
• 卷排序：103

文摘

Combination of cisplatin and belinostat is synergistic in NSCLC. Belinostat apparently circumvent cisplatin resistance. Belinostat increased cellular cisplatin accumulation by inhibiting ABCC2 efflux. Belinostat downregulated ABCC2 by increasing binding of a repressor to the promoter. Belinostat inhibited DNA repair by downregulating the DNA repair gene ERCC1.